SENTI-202
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
What will happen during the trial?
This is a dose-finding study of SENTI-202, comprised of an initial dose finding using a modified "3+3" study design to determine the maximum tolerated dose (MTD) and recommended phase two dose (RP2D) of SENTI-202 when administered after lymphodepleting chemotherapy (Part 1) followed by disease-specific expansion cohorts at the RP2D (Part 2).
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 21 patients (estimated)
- Sponsors
- Senti Biosciences
- Tags
- Natural Killer (NK) Cells (Allogeneic), CD33, FLT3
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1857
- NCT Identifier
- NCT06325748
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.